Lipocine Goodwill and Intangible Assets 2012-2025 | LPCN

Lipocine goodwill and intangible assets from 2012 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Lipocine Goodwill and Intangible Assets 2012-2025 | LPCN

Lipocine goodwill and intangible assets from 2012 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$69.6B
Zoetis (ZTS)$69B
Takeda Pharmaceutical (TAK)$48.7B
Daiichi Sankyo, - (DSNKY)$47.9B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$19.3B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.3B
Orion OYJ (ORINY)$11.2B
Eisai (ESAIY)$9.1B
Madrigal Pharmaceuticals (MDGL)$9B
Corcept Therapeutics (CORT)$7.5B
Grifols, S.A (GRFS)$6.9B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.9B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B